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Once upon a time, immunology was a black box, inflammatory and autoimmune diseases were a
mystery, and relatively blunt tools were used to treat these diseases. In the last 40 years, advances
in molecular biology, DNA recombination technology, and genome sequencing allowed immunol-
ogists to open the box. As the complexity and diversity of the immune response are unveiled,
targeted cellular and molecular therapies now offer rational approaches to treat immune-mediated
diseases. Here, we discuss how the tried and true bench-to-bedside strategies resulted in some
spectacular successes, along with some puzzling failures. Conversely, the advent of targeted
therapies in the clinic has led to a wealth of information that changes how we think about the
pathogenesis of immune-mediated diseases and howwe categorize disease. In turn, these insights
can inform next-generation drug discovery and refine targeted therapies for the appropriate patient
subsets.Introduction—A Glimpse into the Not-Distant Past
Therapeutic intervention using products of immune cells dates
back to the late 19th century with the development of antidiph-
theria toxin by Emil von Behring and Shibasaburo Kitasato.
However, in the 1970s, immunology was regarded by many
molecular biologists and biochemists as a soft science—heavily
phenomenological with limited molecular understanding of the
immune response. Erythropoietin, prolactin, and interferon had
been isolated in the 1960s, but the ‘‘gemisch’’ of cytokines
studied by immunologists in this era was derisively referred to
as ‘‘lymphodreck’’ (Oppenheim and Gery, 1993). Only in 1974,
Zinkernagel and Doherty would report that the ability of T cells
to mount an immune response requires foreign and, surprisingly,
self-encoded antigens. That is, virus-infected fibroblasts were
killed only if the T cells were derived from a genetically identical
strain of mice. The molecular basis of this phenomenon is gene
products known as major histocompatibility antigens, a concept
that explains ‘‘self’’ and ‘‘non-self’’ recognition, which was
awarded the Nobel Prize in Physiology or Medicine in 1996.
Although this breakthrough had profound implications for
understanding diseases that disrupted self-tolerance, in 1974,
most diseases were still characterized just as a collection of
symptoms with no mechanistic understanding of their patho-
physiology. Psoriasis, today recognized as an IL-23-mediated
autoimmune skin disease used to be described as a ‘‘scaling
dermatosis of unknown etiology,’’ for instance.
The molecular cloning of interleukins and hundreds of other
factors dramatically changed the landscape of immunological
research. Further fueling the revolution were advances in
fluorescence-based flow cytometry, recombinant DNA tech-nology, and development of monoclonal antibody (mAb) tech-
nology. These tools enabled dissection of what once was
thought to be a homogeneous CD4+ T cell population to what
actually represents a large family of different lineages/subsets
from Th1 to Th22 cells and various regulatory T cells. Discovery
of receptors and coreceptors, adhesion molecules, and
downstream signaling pathways provided a more precise
understanding of immunity and how immune deregulation can
result in disease.
The opportunity and challenges provided by these basic
discoveries were how basic knowledge about the functioning
of the immune system could be used to treat immune-mediated
disease. The spectrum of molecules and cells identified facili-
tated the development of what would become known as
‘‘targeted therapies’’ (Figure 1). In contrast to drugs identified
empirically found to be ‘‘immunosuppressive’’ in cell-based
assays, molecular techniques identified key nodes, both extra-
cellular and intracellular, against which therapies could be
designed and deployed. Just as the complexity of immunology
has evolved over the past 40 years, our understanding of human
diseases likewise advanced. Nowadays, with a greater in-depth
cellular and molecular understanding of immunological disease,
the heterogeneous nature of autoimmune disorders has become
more apparent. Greater delineation of the underlying pathogenic
mechanisms of autoimmune diseases began to enable the
identification of patient subsets whose diseases are driven by
different biological mechanisms, thus improving our ability to
match new and old therapies for each of these subsets.
In this article, we will highlight some of the triumphs and disap-
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Figure 1. Timeline of Targeted Therapies
Selected examples of recombinant cytokines and cytokine receptors,
monoclonal antibodies (mAbs), and small molecules illustrate the evolution of
targeted therapies.
228 Cell 157, March 27, 2014 ª2014 Elsevier Inc.into impactful therapeutics and how these have shaped our
current therapeutic paradigms. We will focus particularly on a
sampling of therapeutic targets that have revealed new insights
into basic biology and the pathogenesis of human immune-
mediated disease, illustrating themes that relate to success
versus failure. We will touch on the challenges in designing
targeted therapies, ranging from blocking secreted cytokines
to deleting immune cells and how the intricacy of the immune
system impacts these strategies. Given the pleiotropic effects
of cytokines, complexity of cytokine receptors, and human
disease heterogeneity, we discuss what was anticipated of
targeted therapies and substantiated in the clinic as well as the
surprises—both good and bad. We will look for lessons that
can be gleaned and what these lessons might mean for the
development of next-generation targeted therapies. First
though, a brief historical perspective is in order.
Immune Therapies: The Oldies but Goodies
In considering the lessons provided by the new generation of tar-
geted therapies, it is worth revisiting some classic drugs and
considering the implications of their use. Many of these drugs
arose from natural compounds, and their immunosuppressive
activitieswere foundempirically andnotbydesign, acetylsalicylic
acid being one such example (Dinarello, 2010). Corticosteroids,
endogenous immunosuppressive molecules, were first isolated
in the 1940s. Though revolutionary, their toxicities limited their
long-term use. Nonetheless, clinicians devised dosing regimens
that provided efficacy while limiting, albeit incompletely, adverse
effects. Cyclosporine, a fungal product, was first employed as an
antifungal antibiotic and later recognized to have immunosup-
pressive properties. Its target too is ubiquitously expressed,
and therefore, it presents many nonimmunologic side effects.
The first synthetic class of small molecules used to treat autoim-
mune diseases and transplantation were antimetabolites co-
opted from oncology, including azathioprine, methotrexate, and
cyclophosphamide. In the era of targeted therapies, it may be
easy to dismiss the importance of these agents, but it is worth
emphasizing that these drugs remain useful therapeutic options
in many autoimmune diseases nonetheless. In many cases,
even ‘‘blunt’’ drugs likecyclophosphamide (derived frommustard
gas!) can be the right drug for the right patient at the right time.
Cytokines and Cytokine Antibodies: The Beginnings
of Targeted Therapies
The groundbreaking efforts of Berg, Cohen, and Boyer in recom-
binant DNA expression technology in the 1970s provide the
foundation for commercial biotherapeutics. Human insulin was
the first commercialized product based on recombinant DNA
technology and was approved in 1982 for the treatment of type
1 diabetes mellitus (DM) (Figure 1). Within the next decade, ten
additional cytokines, growth factors, or enzymes were approved
for human use. The pioneering work of Kohler and Milstein in
1975 with the discovery of mAb technology enabled the
development of therapeutic antibodies. Development of anti-
body humanization technologies and the ability to generate
human antibodies have overcome immunogenicity problems
of mouse antibodies and are now the standards for human
use (Figure 1 and Table 1). In the next section, we will discuss
Table 1. A Summary of Selected Targeted Therapies: 1986–Present
Target Mechanism Molecule Type
Brand Name
(Generic Name)
Approval/ Clinical
Phase Clinical Application
Targeting Cytokines and Cytokine Receptors
Type 1 IFNs antiviral cytokine Intron A (interferon a 2b) approved 1986 chronic HBV and HCV;
hairy cell leukemia;
malignant melanoma;
AIDS-associated KS
Type 1 IFNs antiviral cytokine Roferon (interferon a 2a) approved 1999 chronic HCV
Type 1 IFNs antiviral cytokine Infergen (interferon
alfacon 1)
approved 1997 chronic HCV
Type 1 IFNs antiviral cytokine Pegintron (peginterferon
a 2b)
approved 2001 chronic HCV
Type 1 IFNs antiviral cytokine Pegasys (peginterferon
a 2a)
approved 2002 chronic HBV and HCV
Type 1 IFNs anti-IFNa humanized
IgG1 mAb
rontalizumab phase II
(completed)
SLE: benefit observed only
in IFN-low subgroup
(NCT00962832)
Type 1 IFNs immunosuppression cytokine Rebif (interferon b 1a) approved 2002 RRMS
Type 1 IFNs immunosuppression cytokine Betaseron (interferon b 1b) approved 1993 RRMS
Type 1 IFNs immunosuppression cytokine Avonex (interferon b 1a) approved 1996 RRMS
IL-2 antitumor cytokine Proleukin (aldesleukin) approved 1992 metastatic renal cell cancer
IL-2 Treg cell expansion cytokine low dose Proleukin
(aldesleukin)
phase II
(completed)
benefit in GVHD
(NCT00529035)
benefit in HCV-associated
cryoglobulinemia
(NCT00574652); worsening
in type 1 DM (NCT00525889)
IL-2 Treg cell expansion immunocomplex IL-2/ anti-IL2 mAb
(JES6.1)
preclinical stage autoimmune diseases
IL-2 expansion of NK
and CD8 T cells
immune complex IL-2/ anti-IL2 mAb
(S4B6, MAB602)
preclinical stage antitumor therapy
IL-2 expansion of NK
and CD8 T cells
superkine IL-2 superkine preclinical stage antitumor therapy
IL-2 anti-IL-2Ra mAb chimeric IgG1 mAb Simulect (basiliximab) approved 1998 acute organ rejection
IL-2 – humanized IgG1 mAb Zenapax (daclizumab) approved 1997;
withdrawn 2011
acute organ rejection;
benefit observed in RRMS
TNF TNFRI-Fc fusion receptor lenercept terminated worsens RRMS
TNF TNFRII-Fc for
TNFa and LTa
fusion receptor Enbrel (etanercept) approved 1998 RA, JIA, PsA, AS, psoriasis;
no benefit in CD
TNF Anti-TNFa mAb chimeric IgG1 mAb Remicade (infliximab) approved 1998 RA, CD, UC, AS, PsA
TNF anti-TNFa mAb human IgG1 mAb Humira (adalimumab);
Simponi (golimumab)
approved 2002;
approved 2009
RA, CD, UC, AS, PsA, JIA,
psoriasis; RA, UC, AS, PsA
TNF anti-TNFa Fab humanized Fab Cimzia (certolizumab
pegol)
approved 2008 RA, CD, AS, PsA
IL-1 IL-1Ra recombinant protein Kineret (anakinra) approved 2001 RA and CAPS
IL-1 IL-1R1/IL-RAcP fusion receptor Arcalyst (rilonacept) approved 2008 CAPS
IL-1 anti-IL-1b mAb human IgG1 mAb Ilaris (canakinumab) approved 2009 CAPS
IL-6 anti-IL-6R mAb humanized IgG1 mAb Actemra (tocilizumab) approved 2005
(Japan);
approved 2010
Castleman’s disease; RA,
polyarticular JIA,
systemic JIA
IL-6 anti-IL-6R mAb human IgG1 mAb sarilumab phase III RA
IL-6 anti-IL-6 mAb human IgG1 mAb sirukumab phase III RA
(Continued on next page)
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Table 1. Continued
Target Mechanism Molecule Type
Brand Name
(Generic Name)
Approval/ Clinical
Phase Clinical Application
Targeting T Cells
TCR anti-CD3 mAb mouse IgG2a mAb OKT3 (muronomab-CD3) approved 1986
(withdrawn
by sponsor in 2012)
transplant rejection
All T cells anti-T cell antisera rabbit
anti-thymoglobulin
Thymoglobulin
(anti-thymocyte globulin)
approved 1998 transplant rejection
Lymphocytes,
monocytes,
dendritic cells
anti-CD52 mAb humanized IgG1 mAb Campath (alemtuzumab) approved 2001 CLL, cutaneous
T cell lymphoma
CD28 CTLA-Fc
costimulatory
blockade
receptor fusion Orencia (abatacept) approved 2005 RA
Helper T cells anti-CD4 mAb mouse IgG1 mAb 16H5; BB14; BF5 terminated –
Helper T cells anti-CD4 mAb mouse IgG2a mAb 19THY5D7; BL4; MT151 terminated –
Helper T cells anti-CD4 mAb rat IgG1 mAb YNB46.1.8 terminated –
Helper T cells anti-CD4 mAb chimeric IgG1 mAb keliximab; priliximab terminated –
Helper T cells anti-CD4 mAb chimeric primatized
IgG4 mAb
clenoliximab terminated –
Helper T cells anti-CD4 mAb humanized IgG cedelizumab; MDX-CD4 terminated –
Helper T cells anti-CD4 mAb humanized IgG1 mAb 4162W94; Campath 9H;
tregalizumab
terminated –
Helper T cells anti-CD4 mAb humanized IgG1 mAb
(FcRn enhanced)
MTRX1011A terminated –
Helper T cells anti-CD4 mAb human IgG1 mAb zanolimumab terminated –
IgE anti-IgE mAb humanized IgG1 mAb Xolair (omalizumab) approved 2003 moderate to severe asthma
Product of
Th2 cells
anti-IL-13 mAb humanized IgG4 mAb lebrikizumab phase III asthma
Product of
Th2 cells
anti-IL-5 mAb humanized IgG1 mAb mepolizumab phase III asthma
Th2 cells anti-IL-4Ra mAb human IgG4 mAb dupilumab phase II asthma
Th1/Th17 cells anti-p40 mAb human IgG1 mAb Stelara (ustekinumab) approved 2009;
phase II
(completed)
psoriasis, CD
Product of
Th17 cells
anti-IL-17A/A mAb human IgG1 mAb secukinumab phase III;
phase II
psoriasis, RA,
AS, RRMS
Product of
Th17 cells
anti-IL-17RA mAb human IgG2 mAb brodalumab phase III psoriasis
Product of
Th17 cells
anti-IL-17A/A;
A/F mAb
humanized IgG4 mAb ixekizumab phase III psoriasis
Targeting B Cells
B cells anti-CD20 mAb chimeric IgG1 mAb Rituxan (rituximab) approved 2006 RA, AAV, MPA
B cells anti-BAFF/BLys
mAb
human IgG1 mAb Benlysta (belimumab) approved 2011 SLE
B cells anti-CD20 mAb humanized IgG1 mAb ocrelizumab phase III RRMS, PPMS
B cells anti-CD20 mAb
(enhanced
complement
activation)
human IgG1 mAb Arzerra (ofatumumab) approved 2009
(phase III)
B-CLL (pemphigus
vulgaris)
(Continued on next page)
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Table 1. Continued
Target Mechanism Molecule Type
Brand Name
(Generic Name)
Approval/ Clinical
Phase Clinical Application
Targeting Intracellular Signaling Components with Small Molecules
mTOR/
FKBP12
inhibitor bacterial macrolide Rapamune (sirolimus) approved 1999 renal transplantation
rejection
S1P1R agonist fungal metabolite Gilenya (fingolimod) approved 2010 RRMS
JAK inhibitor specificity JAK1/2 Jakafi (ruxolitinib) approved 2011 myelofibrosis
JAK inhibitor specificity JAK1/2/3 Xeljanz (tofacitinib) approved 2012 RA
BTK inhibitor – Imbruvica (Ibrutinib) approved 2013 mantle cell
lymphoma; B-CLL
Unknown;
modulates
nuclear factor-2
pathway
– – Tecfidera
(dimethyl-fumarate)
approved 2013 RRMS
PI3K-d inhibitor – Idelalisib phase III refractory indolent
NHL, B-CLL
HDAC inhibitor – Zolinza (vorinostat) approved 2006 cutaneous T cell
lymphoma
HDAC inhibitor – Istodax (romidepsin) approved 2009 cutaneous T cell lymphoma
HDAC inhibitor – panobinostat phase III lymphoma
HDAC inhibitor – CI-994 phase III non-small-cell lung carcinoma
Abbreviations: AAV, ANCA-associated vasculitis; AS, ankylosing spondylitis; CAPS, cyropyrin-associated periodic syndromes; CD, Crohn’s disease;
CLL, chronic-lymphocytic leukemia; HBV, hepatitis B virus; HCV, hepatitis C virus; JIA, juvenile idiopathic arthritis; KS, Kaposi sarcoma; MPA, micro-
scopic polyarteritis; NHL, non-Hodgkin lymphoma; PPMS, primary progressive multiple sclerosis; PsA, psoriatic arthritis; RA, rheumatoid arthritis;
RRMS, relapsing remitting multiple sclerosis; SLE, systemic lupus erythematosus.the advantages and pitfalls of the prominent classes of cytokines
and antibodies that have emerged as candidates for targeted
therapy.
Type 1 IFNs
Interferons (IFNs), as indicated by their name, interfere with viral
infections (Pestka, 2007). The type I IFNs, comprising 12 different
a subtypes, b, ε, k, and u IFNs, are ubiquitously induced by viral
and bacterial infections but are predominantly produced by
plasmacytoid dendritic cells (pDCs). They bind a common
IFNa/b (IFNAR) heterodimeric receptor, inducing hundreds of
genes termed interferon-stimulated genes (ISGs) that mediate
a wide array of biological functions, including both activating
and inhibitory immunomodulatory effects (Gonza´lez-Navajas
et al., 2012).
Type 1 IFNas are approved for cancer treatment based on
their antiproliferative and immune adjuvant effects (Table 1).
They are also approved for treatment of hepatitis B and C
(HBV and HCV, respectively), based on their direct inhibitory
effect on viral replication, through the induction of antiviral genes
like ISG15, Mx GTPases, RNase L, PKR (Sadler and Williams,
2008), and immunostimulatory activities. Although IFNa has
served as the backbone for HCV therapy, the advent of viral pro-
tease, polymerase, and replication complex inhibitors in
IFNa-free treatment regimens has significantly changed the
HCV treatment landscape. In studying patients that spontane-
ously resolve HCV infection, as well as those successfully
treated, a robust multiepitope CD4+ and CD8+ memory T cell
response to HCV appears to be a requisite for viral control
(Schmidt et al., 2013). Patients unable to clear HCV infectionsare more likely to have transient and weak T cell responses
that react to a limited spectrum of HCV epitopes. In addition,
HCV-reactive T cells are intrinsically dysfunctional, possibly
due to expression of inhibitory receptors (e.g., PD1 or CD279)
on T cells or ligands for inhibitory receptors (e.g., PDL1) on other
cell types. In vitro blockade of PD1 or the addition of IL-2 restores
T cell functions (Urbani et al., 2006). The recent discovery of a
diagnostic marker, SNPs linked to the IL28B (l3) gene, which
predicts patient response to IFNa therapy (Ge et al., 2009),
should also provide mechanistic insights into host-pathogen
interactions to improve curative paradigms for the treatment of
HCV and other chronic viral illnesses (e.g., HBV and HIV), as
well as for cancer immunotherapy.
Whereas exogenous IFNa is of therapeutic benefit in chronic
viral diseases, overproduction of type I IFNs can tip immune
balance and cause autoimmune disorders (Lichtman et al.,
2012). Indeed, a small fraction of patients treated with IFNa
develops systemic lupus erythematosus (SLE). In two-thirds of
patients with SLE, a prototype autoimmune disorder character-
ized by the production of autoantibodies, high levels of ISGs
are detected in peripheral blood cells of patients (designated
as ‘‘IFN-high’’ SLE) (Baechler et al., 2003). Interestingly, treat-
ment of SLE patients with an anti-IFNa mAb (rontalizumab,
NCT00962832) provided clinical benefit only in the IFN-low
subset of patients and reiterated the need for diagnostic markers
(e.g., IFN signature) to guide therapeutic choices.
Paradoxically, IFNs are approved for another disease, a
relapsing and remitting form of multiple sclerosis (RRMS), based
on the immunosuppressive actions of IFN b-1 (Dhib-Jalbut andCell 157, March 27, 2014 ª2014 Elsevier Inc. 231
Figure 2. Lessons Learned and Challenges AheadMarks, 2010). What is especially mystifying is that all type I IFNs
bind the same IFNAR complex. How binding of different ligands
to the same receptor complex triggers a broad range of different
biological responses remains a puzzling question for which there
is yet no definitive answer. The recent description of the unique
ability of IFNb to bind IFNAR1 and transduce signals in a Jak/
STAT-independent manner in the absence of IFNAR2 compared
to the requirement for IFNAR1/2 for IFNamay provide a mecha-
nistic basis for this paradoxical phenomenon (de Weerd et al.,
2013). As we will further discuss, paradoxical actions of a cyto-
kine are not an exclusivity of interferons. Rather, understanding
how a single cytokine produces different biological effects and
how different molecules use a limited set of receptor to produce
a broad range of responses is one of the main challenges in
designing targeted therapies (Figure 2).
Interleukin 2
IL-2 and the IL-2 receptor (IL2R) were the first cytokine and cyto-
kine receptors to be cloned (Boyman and Sprent, 2012; Malek
and Castro, 2010). Produced predominantly by activated CD4+
T cells, IL-2 is the prototypic, autocrine T cell growth factor.
Based on these immunostimulatory actions, IL-2 was approved
for metastatic renal cell carcinoma in 1992. A limiting toxicity of
IL-2 is vascular leak syndrome (VLS) and relates in part to the
fact that endothelial cells express IL2Rs and release proinflam-
matory cytokines and vasoactive mediators. By virtue of
their ability to block the immunostimulatory effects of IL-2, dacli-232 Cell 157, March 27, 2014 ª2014 Elsevier Inc.zumab, and basiliximab, anti-IL-2R mAbs are approved for the
prevention of acute organ rejection.
The biology of IL-2 turns out to be more complex than just its
immunostimulatory role and thus provides some interesting
lessons for targeted therapies. A major surprise that reshaped
our view of IL-2 function was that Il2/, Il2ra/, and Il2rg/
mice develop systemic autoimmunity. This counterintuitive
phenotype is due to the requisite role of IL-2 in Foxp3+ regulatory
T cells (Tregs), a cellular subset that was recognized long after
the discovery of IL-2. Like IFNs, IL-2 has both pro- and anti-
inflammatory actions. The latter effect can limit antitumor
efficacy but may also provide new therapeutic opportunities.
Aside from actions on diverse cell populations, other factors
help to explain the complexity of action of IL-2. The IL-2R
consists of the IL2Ra (CD25), IL2Rb (CD122), and the common
cytokine receptor gc (CD132) subunits. IL2Ra is not involved in
signaling but rather influences affinity, and differential expres-
sion of these three receptor subunits on distinct immune cell
types accounts for varying activities of IL-2. To improve efficacy
and to diminish toxicities, efforts have been made to selectively
target IL-2 to the IL2Rb/gc complex and thereby preferentially
activate CD8+ and natural killer (NK) cells and promote tumori-
cidal activity. An immunocomplex of IL-2 coupled with an anti-
IL-2 mAb (e.g., S4B6 and MAB602) favors IL-2Rb/gc binding
and provides superior antitumor activity in mice. Alternatively,
selective IL-2 targeting can also be achieved by generating
IL-2 ‘‘superkines’’ with improved binding to IL2Rb (Levin et al.,
2012). Hence, selective activation of different cell types by
engineered ‘‘superkines’’ or immunocomplexes may provide
greater therapeutic benefit with less toxicity.
Conversely, IL-2 immunocomplexes (e.g., JES6.1) that favor
binding to IL2-Ra can drive Treg cell expansion and function
and limit autoimmune disease (Boyman and Sprent, 2012). The
concept of expanding Treg cells to tame autoimmunity has
gained recent clinical validation with efficacy observed in
the treatment of graft-versus-host disease (GVHD) and HCV-
associated cryoglobulinemia—a type of vasculitis—though the
same low-dose IL-2 regimen in combination with rapamycin
resulted in clinical worsening of type 1 DM (NCT00529035,
NCT0574652, and NCT00525889). New insights have also
come from the use of daclizumab (a monoclonal antibody spe-
cific for IL-2-Ra) in RRMS patients (Bielekova, 2013; Martin,
2012). As expected, daclizumab decreases Treg cells, but it
also increases CD56bright CD122hi NK cells that have novel
immunosuppressive functions.
Despite being the first cytokine cloned 31 years ago, new
aspects of the biology of IL-2 continue to be revealed. Coupled
to the identification of ‘‘new’’ cellular subsets, such as Foxp3+
Treg andCD56bright CD122hi NK cells, the capacity tomanipulate
distinct receptor complexes provides the ability to capitalize
upon the seemingly paradoxical functions of this prototypic
cytokine. Understanding its complex actions and dissecting of
its role in immune homeostasis should allow more effective
therapeutic use of this fascinating cytokine and its antagonists.
Tumor Necrosis Factor
Tumor necrosis factor (TNF) is the archetype cytokine of a 19
member TNF superfamily and a 32 member TNF superfamily of
receptors (Aggarwal et al., 2012). Its discovery as a serum
substance found in mice infected with bacillus Calmette-Guerin
that selectively induced necrosis of tumor cells provides the
basis for its coining ‘‘tumor necrosis factor.’’ Gene cloning of
TNFa and identification of its receptors TNFR1 and TNFR2
enabled the field to rapidly explore potential therapeutics.
TNFa is synthesized and presented on the cell surface as a
type 2 transmembrane protein. Cleavage of membrane TNFa
(mTNFa) by a TNFa-converting enzyme gives rise to its secreted
(sTNFa) form. Both forms bind and activate TNFRs. Conversely,
binding of TNFRs tomTNFa can confer ‘‘reverse signaling’’ to the
mTNFa-bearing cell. Biological consequences of this ‘‘reverse
signaling’’ include secretion of IL-2 and IFNg by T cells and
increased cytotoxicity by NK cells.
Based on the discovery of TNFa as a tumor necrosis-inducing
agent, initial drug discovery efforts were focused on cancer
treatment (Palucka et al., 2005), but results showed minimal
efficacy and were associated with significant toxicity. Because
TNFa is also induced in bacterial sepsis, early drug discovery ef-
forts also tested TNF antagonists in this setting. Eleven random-
ized placebo-controlled studies involving >7,000 patients testing
three different anti-TNFamAbs, TNFR1-Fc, and TNFR2-Fc failed
to demonstrated benefit of anti-TNF therapy for sepsis.
The subsequent testing of TNFa antagonists in inflammatory
diseases was supported by the presence of TNFa as part of
the ‘‘lymphodrek’’ in the synovial fluid of rheumatoid arthritis
(RA) patients (Feldmann, 2002). Treatment of synovial cultures
with anti-TNFa mAbs decreased IL-1, GM-CSF, and IL-6 levels,
suggesting that TNFa may be at the top of a cytokine cascade.
Overexpression of a TNFa transgene in mice, in which a 30
regulatory element was deleted that resulted in TNFa over-
production, caused erosive polyarthritis and inflammatory bowel
disease (IBD). These preclinical studies provided the basis for
broad clinical experimentation in humans over the past 22 years.
To date, there are five Food and Drug Administration (FDA)-
approved TNFa antagonists. As a therapeutic class, TNFa
antagonists represent the largest commercial class of therapeu-
tics with more than 25 billion dollars of annual sales.
TNF antagonists offer interesting lessons, again pointing to
unanticipated immunosuppressive roles of prototypic proinflam-
matory cytokines. Although Tnfa/ mice or mice treated with
TNFa antagonists have delayed onset of experimental autoim-
mune encephalitis (EAE), a phase II study of patients with MS
with the TNF blocker, lenercept, demonstrated worsening of
disease (The Lenercept Multiple Sclerosis Study Group and the
University of British Columbia MS/MRI Analysis Group, 1999).
Preclinical work indicates that TNFR2 is required for oligoden-
drocyte regeneration, whereas TNFR1 promotes autoimmunity
(Arnett et al., 2001), raising the possibility that selective inhibition
of TNFR1 might be clinically useful. Additionally, TNFa inhibits
plasmacytoid DC IFNa production, and patients treated with
TNFa antagonists demonstrate increased ISGs (Palucka et al.,
2005). These and other mechanisms likely account for some of
the autoimmune phenomena (e.g., increased autoantibodies)
and toxicities (e.g., worsening of RRMS) observed with anti-
TNF treatment.
Another aspect to consider is the effectiveness of infliximab,
an anti-TNFa monoclonal antibody, but not of etanercept, a
TNFRII-Fc fusion receptor, in the treatment of Crohn’s disease,a form of IBD. This differential effect led to important questions
as to whether the efficacy of different biologicals that target
TNFa relate to their ability to affect the function of membrane-
bound versus soluble TNFa. Membrane-bound TNFa is impor-
tant for protective immunity and lymphoid organization, except
for primary B cell follicle formation, which is reliant on sTNFa
(Nielsen and Ainsworth, 2013; Ruuls et al., 2001). Conversely,
sTNFa plays a dominant role in several inflammatory conditions,
except for IBD. One plausible explanation for the differential
efficacy of infliximab and etanercept in Crohn’s disease was
that infliximab would have the unique ability to induce apoptotic
cell death. However, this model has been put into question
because another TNFa-targeting drug, certolizumab pegol
(CZP), also binds mTNFa and has shown clinical efficacy in
Crohn’s disease but does not induce apoptosis. This conundrum
may be partly enlightened by the ability of infliximab and CZP to
induce mTNFa signaling that downregulates proinflammatory
signals without inducing apoptosis (Derer et al., 2013).
Interleukin-1
IL-1, one of the first cytokines identified, was described in the
1940s as a product of leukocytes termed ‘‘endogenous
pyrogen’’ and is now recognized as a prototypic cytokine that
induces inflammation. Its actions are attributable to two related
gene products, IL-1a and IL-1b (Gabay et al., 2010). Inactive
pro-IL-1b is processed by the inflammasome complex to
generate the active cytokine. There are many products that
activate the inflammasome, ranging from crystals to microbial
products. Like TNF, IL-1b blockade was efficacious in many
models of inflammatory arthritis. Because IL-1 has an endoge-
nous inhibitor, IL-1 receptor antagonist (IL-1Ra), a recombinant
version (kineret) was developed and approved in 2001 for the
treatment of RA.
A collection of genetic autoinflammatory disorders due to
mutations of NLRP3 (designated the cryopyrin-associated
periodic syndromes, CAPS) that result in constitutive inflamma-
some activation and IL-1b secretion has returned IL-1 therapies
to the spotlight (Federici et al., 2013; Gabay et al., 2010;
Goldbach-Mansky and Kastner, 2009). Three IL-1b antagonistis
(anakinra, rilonacept, and canukinumab) are now approved for
these disorders and underscore the power of human genetics
in identifying diseases in which targeted therapeutics may
provide their greatest clinical impact.
Aside from IL-1, the IL-1 family of ligands consists of ten
additional family members. Many of these additional family
members (e.g., IL-18 and IL-33) are genetically linked to autoim-
mune diseases, and much will be learned as these novel cyto-
kines are targeted in the clinic.
Interleukin-6
Produced by many immune and nonimmune cells, IL-6 is the
third member of inflammatory cytokine triumvirate: TNF, IL-1,
and IL-6 (Tanaka et al., 2012). It has widespread effects in B
cell Ig production, induction of acute phase reactants, Th17
cell differentiation, megakaryocyte maturation, and osteoclast
function. Blocking IL-6 is effective in many models of inflamma-
tion, and an anti-IL6R mAb (toclizumab) is approved for Castle-
man’s disease (a rare benign lymphoproliferative disorder of
germinal center B cells), RA, and juvenile idiopathic arthritis
(JIA) (Nishimoto and Kishimoto, 2006).Cell 157, March 27, 2014 ª2014 Elsevier Inc. 233
Given themultitude of therapeutic options for patients with RA,
how then might physicians choose the appropriate therapy for
patients? In fact, there are few biomarkers that help guide
therapy (Daı¨en andMorel, 2014). A recent analysis of rheumatoid
arthritis synovial transcriptome has identified four major pheno-
types (Dennis et al., 2014). Each phenotype has a distinct
underlying gene expression signature reflecting different cellular
compositions and correlating with differential clinical responses
to adalimumab and tocilizumab treatment. This is clearly an
important area to pursue.
Targeting Cytokine Signaling: The Jakinibs
In addition to directly blocking cytokines and cytokine receptors,
an alternative strategy is to interfere with receptor down-
stream signaling. The possibility that cytokine signaling could
be targeted by small molecules stemmed from several
developments—some derived from basic research and some
from clinical studies of a cohort of patients with a rare disease.
The importance of reversible protein phosphorylation in signal
transduction along with the elucidation of the human kinome
facilitated the development of therapeutically useful kinase
inhibitors (Manning et al., 2002). With their prominent role in
cancer, protein tyrosine kinases (PTKs) became obvious targets,
although developing specific PTK inhibitors was challenging.
Some of the first PTK inhibitors, like genistein and herbimycin
A, were natural products isolated from fungi, and their poor
target specificity limited their therapeutic usefulness. Aided by
new insights into the protein structure of kinases and increasing
sophistication ofmedicinal chemistry, many successes emerged
stemming from structure-enabled rational drug design and high-
throughput screening approaches. Imatinib, for example, revolu-
tionized the treatment of chronic myeloid leukemia (Druker et al.,
2001), and now kinases are among the most attractive targets in
cancer therapeutics, with 20 FDA-approved inhibitors.
Many key immune receptors initiate signaling via PTKs linked
to downstream serine-threonine kinases. Cytokines that bind
type I and type II cytokine receptors constitute an excellent
example. They comprise a range of factors that include inter-
leukins, interferons, colony stimulating factors, and hormone-
like cytokines, and all exert their effects through Janus kinases
(JAKs) (Leonard and O’Shea, 1998). Specifically, the intracel-
lular domains of cytokine receptors selectively bind to different
JAKs (TYK2, JAK1, JAK2, and JAK3) in various combinations.
Mutant cell lines initially revealed the criticality of TYK2,
JAK1, and JAK2, but the first in vivo proof of the importance
of JAKs came from the discovery of children with severe com-
bined immunodeficiency and JAK3 mutations. Gene knockout
mice subsequently confirmed the essential, nonredundant
functions of the JAKs.
The first JAK inhibitor (jakinib) to be tested in humans was
tofacitinib (Changelian et al., 2003). Tofacitinib was approved
for moderate-to-severe RA and has shown efficacy in ulcerative
colitis (UC) and psoriasis (Sandborn et al., 2012; Strober et al.,
2013). The initial strategy underlying the development of tofaciti-
nib was JAK3’s critical role in immunity. Although tofacitinib was
intended to be a JAK3 inhibitor, in reality, it also inhibits JAK1
and, to a lesser extent, JAK2. One might assume that this could
be a drawback, given lethal phenotypes associated with Jak1/234 Cell 157, March 27, 2014 ª2014 Elsevier Inc.or Jak2/mice. In fact, use of tofacitinib is associated with mild
to moderate anemia. Moreover, the discovery that gain-of-func-
tion JAK2 mutations that underlie myeloproliferative disorders
provided a rationale for purposefully targeting JAK2. Ruxolitinib,
a JAK1 and JAK2 inhibitor, was approved for myelofibrosis
(Verstovsek et al., 2010) and was the first JAK inhibitor approved
for human use.
There are useful lessons offered by first-generation jakinibs
(O’Shea et al., 2013). First, because they affect multiple JAKs,
they interfere with multiple cytokines that contribute to RA
immunopathogenesis. As a result, these drugs inhibit both
adaptive and innate immunity. Thus, jakinibs provide a good
example of how genetics can both inform and mislead drug
development. A priori, a reasonable expectation was that selec-
tivity would be critical for the development of a successful drug
and inhibition of JAK2 would be problematic. However, this may
be less detrimental than expected, and interfering with multiple
cytokines has the benefit of modulating both innate and adap-
tive immunity.
Another point to consider is that, although jakinibs interfere
with cytokines, unlike the other mAbs previously discussed,
they do not provide long-term inhibition; thus, a potential advan-
tage of small molecule inhibitors is their short half-lives. Drug
discontinuation typically results in rapid reversibility of the
immunomodulatory effects when compared to mAbs that
have longer half-lives. Much is still to be learned from the
next-generation jakinibs with different ratios of JAK1:2:3:Tyk2
inhibition and how these differences may translate into efficacy
and toxicities.
Targeting T Cells and Their Products
Polyclonal preparations of rabbit or equine antihuman thymo-
cyte globulin have been used for allograft rejection and aplastic
anemia since the late 1990s. Unfortunately, their use was
complicated by cytokine release syndrome and immunogenicity
to rabbit/equine antibodies, resulting in serum sickness. Given
the importance of T cells in autoimmune disease and organ
rejection, significant efforts were focused on generating mono-
clonal antibodies to target T cells specifically. The identity of
these antibody targets, however, was often not known until
much later. A mAb against the T cell receptor (TCR) complex
(anti-CD3 Ab or OKT3) was the first to be approved and
commercialized for use in solid organ allograft rejection (Table 1).
Another such anti-T cell mAb was anti-CD52 mAbs (CAMPATH-
1M, G, H, or alemtuzumab) that demonstrate clinical efficacy in
GVHD, non-Hodgkin’s lymphoma, vasculitis, and RRMS
(Waldmann and Hale, 2005). The target antigen was discovered
to be CD52, a glycosylphosphatidylinositol-linked protein ex-
pressed on T cells and also on other immune cells. The
breadth of expression contributes not only to its clinical effec-
tiveness but also its toxicities, including prolonged cytope-
nias, paradoxical autoimmunity, and opportunistic infections.
The recent description of a suppressive CD52+CD4+ T cell pro-
vides additional mechanisms for alemtuzumab action either
through depletion of CD52+ suppressor cells and/or binding
and neutralization of the immunosuppressive activities of solu-
ble CD52 released from CD52+ T cells (Bandala-Sanchez
et al., 2013).
Anti-CD4 mAbs offered the first opportunity to selectively
target CD4+ T cells at a time when we did not fully appreciate
Th cell heterogeneity (Isaacs et al., 1997). Preclinical experimen-
tation had demonstrated robust efficacy of anti-CD4 mAbs in
SLE, EAE, inflammatory arthritis, GVHD, and tolerance induc-
tion. More than a dozen different anti-CD4 antibodies have
entered clinical testing and can be segregated into four genera-
tions, reflecting the many obstacles encountered (Table 1).
Those include immunogenicity, long-lasting depletion of CD4+
T cells, short drug half-life due to internalization, clearance of
the bound antibody, and surprisingly, development of dose-
limiting rash. Overall, targeting CD4 has not been a clinically
or commercially attractive venture. Based on these experi-
ences, one might assume that wholesale blocking of T cells
would be problematic, but, contrasting with the relative poor
track record of anti-CD4 mAbs is abatacept, a CD152-Fc fusion
protein that inhibits CD28/CD80 (B7.1) and CD86 (B5.2) costi-
mulatory pathways that are important for T cell activation and
acquisition of effector functions. Abatacept is approved for the
treatment of rheumatoid arthritis and a form of arthritis that
develops in children and adolescents called juvenile idiopathic
arthritis (Keating, 2013). Admittedly, targeting costimulation is
much less draconian than depleting T cells, but it is still not
entirely obvious why the outcomes of these two strategies are
so different.
Helper T Cells
With the realization of the heterogeneity of CD4+ T cell subsets,
more recently, drug discovery efforts have focused on target-
ing specific cytokines associated with different CD4+ T cell sub-
populations. In fact, recognition in the late 1970s that CD4+
T cells could present two different flavors, Th1 and Th2, was
just the beginning of understanding the dynamic nature and
heterogeneity of Th cell differentiation (Zhu and Paul, 2008).
Four decades of investigation have led to detailed characteriza-
tion of receptors, signaling events, and transcriptional control
that regulate Th1 cells to secrete IFNg and respond to intracel-
lular bacteria and protozoa; Th2 cells to secrete IL-4, IL-5, and
IL-13 and respond to helminths; Th17 cells to secrete IL-17 to
mediate immunity against extracellular bacteria and fungi; and
Treg cells to secrete IL-10 or TGF-b and dampen immune
responses and inflammation. Dissection of each T helper subset
has permitted more precise targeting of pathogenic T cell
responses without disarming all CD4+ T cell functions.
Th2 Cells
Th2 immunity is associated not only with Th2 cells but also with
accumulation of eosinophils, alternatively activated macro-
phages, basophils and mast cells, elevated IgE, mucus produc-
tion, and smooth muscle hyperplasia (Van Dyken and Locksley,
2013), and aberrant activation of Th2 pathways is associated
with the development of atopic/allergic diseases. Both IL-4
and IL-13 bind a heterodimeric IL13R1/IL4Ra receptor that
signals through a Jak1/Tyk2 pathway. IL-4 has an additional
private IL-4Ra/gc receptor expressed on lymphocytes that
promotes class switching and increases in IgE. IL-13 also has
a private receptor, IL13R2, whose function is not fully under-
stood. In addition to Th2 cells, many other cell types, including
basophils, mast cells, eosinophils, innate-like lymphocyte type
2 cells (ILC2), and NKT cells, secrete IL-4 and IL-13.The impetus to target these pathways in allergic diseases
[atopic dermatitis (AD), allergic rhinitis, and allergic asthma] is
supported, in part, by demonstration that IL-4, IL-5, and IL-13
play important roles in models of allergic lung inflammation
and because of the identification of TSLP, IL4/13, and IL4R
SNPs associated with AD and asthma susceptibility.
There have been several interesting insights gained from
targeting Th2 cytokines. Just as CD4+ T cells are heteroge-
neous, so are asthma patients. Significant efforts have been
put on defining asthma phenotypes based on clinical and
laboratorial parameters. Age of onset, history of atopy, body
mass index, smoking, lung function, serum IgE levels, periph-
eral eosinophilia, and sputum eosinophilia are examples, just
to name a few (Ingram and Kraft, 2012). Eosinophilia and serum
IgE have been utilized to stratify patients for clinical trials. Anti-
IgE (omalizumab) therapy is approved for patients with moder-
ate to severe asthma, and its use and dose are determined, in
part, on serum IgE levels. A significant breakthrough was made
recently with the discovery of a new biomarker, serum perios-
tin—a bronchial epithelial cell gene induced by IL4/13, which
identifies asthma patients who respond to an anti-IL13 mAb
(lebrikizumab) (Arron et al., 2013). Similarly, treatment with an
anti-IL4Ra mAb (dupilumab) or an anti-IL-5 mAb (mepolizumab)
is efficacious in a selected subset of asthma patients with
elevated eosinophil levels (NCT01312961, ISRCTN75169762,
and NCT00292877). These experiences further underscore
the need to develop companion diagnostic tests that reflect a
patient’s underlying disease to enable the best therapeutic
decision.
Additionally, the clinical experiences with targeted Th2 thera-
pies have revealed not only the heterogeneity of human allergic
diseases but also the different contributions within the Th2-
associated cytokines with IL4/13 demonstrating broader inflam-
matory roles and IL-5 having a more restricted role through
eosinophil recruitment. As these Th2 targeting agents progress
in the clinic and because Th2 cytokines are known now to
contribute to other biological processes beyond immunity, we
will learn much more about their contributions not only in allergic
but also in fibrotic and metabolic diseases.
Interleukin-17
The biological understanding of the IL-17 family members in
immunity and disease has rapidly emerged and with some quite
unexpected results (Miossec and Kolls, 2012). IL-17 exists in
three forms: IL-17A/A, IL-17A/F, and IL-17F/F. All three forms
bind IL-17RA/IL-17RC and, through ACT1/TRAF6 signaling,
activate NF-kB. IL-17 operates on a variety of cell types and
synergizes with TNF to promote inflammatory responses. IL-17
family members are important in controlling extracellular bacte-
rial and fungal infections. Development of Th17 cells requires
IL-23 and IL-1b and transcription factors RORa and RORg.
In addition to IL-17A and F, Th17 cells also secrete IL-21,
IL-22, and granulocyte macrophage colony-stimulating factor
(GM-CSF).
Multiple agents are in clinical development to target the IL-17
family members, and the clinical experience has revealed both
concordant and discordant clinical results from IL-12/23 versus
IL-17 neutralization. The most impressive clinical efficacy with
IL-17 and IL12/23 neutralization to date is in psoriasis andCell 157, March 27, 2014 ª2014 Elsevier Inc. 235
Figure 3. Flow of Information in Development of Targeted Therapies
Advances in molecular biology revealed a number of targets that were iden-
tified at the bench and led to successful drugs at the bedside (‘‘bench to
bedside’’). Conversely, though, advances in sequencing technology led to the
discovery of various genetic disorders that also provided convincing targets
for intervention. Such ‘‘experiments of nature’’ facilitated the understanding of
what the consequence of interfering with a target might be and thus provided
impetus to go back to the bench (‘‘bedside to bench to bedside’’). In other
circumstances, development of a targeted therapy did not have the expected
result. Fortunately, in a number of cases, this led investigators to go back to the
bedside and rethink disease mechanisms and find the right disease for the
therapy (‘‘bench to bedside to bedside’’).ankylosing spondylitis (AS) (NCT00809159, NCT01107457,
NCT00267969, and NCT01330901). Disappointingly, whereas
elevated IL-17 levels were first described in synovial fluid of RA
patients, IL-17 antagonists, with the exception of one study,
have not demonstrated efficacy.
In contrast, discordant results have been demonstrated in
RRMS and CD. Secukinumab (anti-IL17A/A mAb) is efficacious
in RRMS (NCT01874340), whereas ustekinumab (anti-IL12/23
mAb) demonstrated no benefit (NCT00207727). This discor-
dance may be explained, in part, by preclinical experiments
that demonstrate a requirement of IL-23 in the priming, but not236 Cell 157, March 27, 2014 ª2014 Elsevier Inc.effector, phase of EAE (Thakker et al., 2007), as well as the ability
of IL-12 to induce IFNg, which is protective in EAE (Gran et al.,
2004). Conversely, whereas ustekinumab is efficacious in
patients with moderate to severe CD (NCT00771667), treatment
of patients with secukinumab resulted in worsened disease
(NCT01009281). Why targeting different points of the Th17 axis
leads to differences in therapeutic outcome for different
diseases remains to be understood. These results nonetheless
exemplify not only how much remains to be learned but also
that results of clinical trials can be informative and offer guidance
to basic research (Figures 2 and 3).
Of note, with respect to the biology of IL-17, it is important to
emphasize that Th17 cells are just one of many types of cells that
produce IL-17 and are likely not itsmost prominent source. Other
producers of IL-17 include gd T cells, innate lymphoid cells
(ILCs), and neutrophils. The importance of Rorgt as a key tran-
scription factor that controls IL-17 production in all these cells
suggests that it might be a reasonable target for generation of
small-molecule inhibitors. Rorg is part of the 48 member nuclear
receptor superfamily, which includes glucocorticoid and steroid
hormone receptors. Remarkably, an old drug, digoxin, can
bind to Rorgt and inhibit IL-17 production (Huh et al., 2011).
Generation of selective Rorg inhibitors is an active area of
research and holds great promise in targeting Th17 biology.
Targeting B Cells
The contribution of B cells to humoral immunity was already sug-
gested in 1952 by Colonel Ogden Bruton with the description of
the case of a boy with history of pneumonia and bacterial respi-
ratory infections who had no serum immunoglobulins (Ig). Bruton
type or X-linked agammaglobulinemia (XLA) would become the
first primary immunodeficiency syndrome to be described.
Patients with XLA suffer a developmental abnormality caused
by mutations in Bruton’s tyrosine kinase (BTK) and lack mature
B cells.
The mechanisms by which B cells contribute to autoimmunity
have exponentially increased since the description of XLA (Pillai
et al., 2011). The pathogenic roles of autoantibodies and immune
complexes were the first to be established. However, B cells also
secrete cytokines and express costimulatory receptors that
contribute to T cell function. In addition, activated B cells are
potent antigen-presenting cells and are found in ectopic
lymphoid aggregates in nonlymphoid organs in autoimmune
diseases, where they promote germinal center (GC) reactions.
Plasmablasts or plasma cells resident within these GC-like
structures secrete autoantibodies that propagate inflammation.
The identification of regulatory B cells that attenuate T cell
responses through IL-10 or TGF-b secretion or through intercel-
lular interactions provides an additional dimension by which B
cell deregulation can contribute to autoimmunity (Mauri and
Bosma, 2012).
The approval of two B-cell-modulating therapies—rituximab
and belimumab—has enabled us to begin understanding the
effects of B cell modulation in humans (Isaacs et al., 1997; Jacobi
and Do¨rner, 2010) (Table 1). Rituximab is a chimeric anti-CD20
mAb that depletes most CD20+ B cells and is approved for
the treatment of autoimmune disorders, including patients
with RA who have failed TNF antagonist therapies,
ANCA-associated vasculitis (AAV), and microscopic polyarteritis
(MPA). Belimumab is an anti-BAFF/BLys mAb that neutralizes a
growth factor critical for B cell survival and is approved for the
treatment of SLE, a disease in which rituximab did not demon-
strate benefit (Merrill et al., 2010; Rovin et al., 2012).
Treatment of patients with rituximab and belimumab has
provided support for many of the proposed B-cell-mediated
mechanisms in autoimmunity. Treatment with rituximab
decreases a subset of autoantibodies that are casually linked
to autoimmune diseases, as well as decreasing IL-6-secreting
B cells and IL-17 production and skewing cytokine profiles that
favor immunosuppression (Barr et al., 2012; Gran et al., 2004).
Treatment of SLE patients with belimumab decreases naive
and activated B cell numbers and anti-dsDNA Abs and normal-
izes complement levels (Stohl et al., 2012).
A surprise in B cell drug discovery was the efficacy of rituximab
therapy observed in patients with RRMS (Hauser et al., 2008). At
the time, the major paradigm was that RRMS was primarily a
T-cell-mediated disease. T-cell-directed therapies were
extremely efficacious in EAE when administered before or after
disease onset, whereas B cell modulation was only effective
before disease onset. Another puzzle yet to be solved is that,
whereas rituximab is efficacious, treatment of RRMS patients
with a TACI-Fc fusion protein (atacicept) that neutralizes both
BAFF/BLys and APRIL (a related family member) results in
disease worsening (NCT00642902).
An additional aspect of B cell modulation therapy is the need
to better understand the status of the immune lymphocyte
repertoire following therapy. Following B cell depletion by ritux-
imab, B cells begin to repopulate the circulation 6 months
following the end of therapy and return to baseline levels
12 months following treatment (Roll et al., 2006). These re-
pleted B cells, however, are mostly naive CD27IgD+ B cells
and not memory CD27+IgD+ B cells, the latter subset requiring
>2 years to return to baseline levels. B cells undergo both central
and peripheral selection processes to delete autoreactive B cells
(Meffre, 2011). Patients with SLE, type 1 diabetes, and rheuma-
toid arthritis demonstrate loss of both central and peripheral
tolerance, whereas patients with MS only demonstrate defects
in peripheral tolerance. Might this difference in selection check-
points contribute to the more sustained clinical effects observed
with B cell depletion therapy in MS? Further analysis of immune
repertoires following B cell modulatory therapies will provide
greater insights into both basic immunology and themechanistic
basis of efficacy or lack of efficacy in the treatment of autoim-
mune diseases.
Targeting Immunoreceptor Signaling
The TCR, B cell receptor (BCR), and Fc receptors (FcRs), are
structurally related, and their shared modes of signal transduc-
tion were elucidated during the late 1980s. Phosphorylation of
receptor subunits on specific tyrosine residues, termed immu-
noreceptor tyrosine-based activation motifs (ITAMs), by SRC
family PTKs recruits the spleen tyrosine kinase (SYK) family of
PTKs by virtue of their tandem SRC homology 2 domains
(Chan et al., 1994a). There are two SYK PTK family members,
ZAP-70 and SYK. Although patients with ZAP70 mutations
have a severe combined immunodeficiency, making this kinasea logical therapeutic target, a successful inhibitor of this kinase
has yet to be developed (Chan et al., 1994b). A candidate clinical
SYK inhibitor, fostamatinib (R788), was developed and demon-
strated utility in preclinical models of allergy, RA and SLE. It
showed promise in initial trials but was terminated in pivotal trials
in RA (NCT00665925, NCT01242514, and NCT01197755). New
clinical trials are evaluating more specific and potent SYK inhib-
itors in the setting of chronic lymphocytic leukemia (CLL) and
autoimmunity. As SYK has important functions outside of the
immune system, including thrombosis and vascular biology,
additional clinical investigation of SYK inhibitors will inform their
suitability in immune and nonimmune-mediated diseases and
potential toxicity liabilities.
Besides the SRC and SYK families of PTKs, a third family, the
TEC PTKs, is important in immunoreceptor signaling. One
member of this family, BTK, is especially notable because
mutations of BTK are often the underlying cause of X-linked
agammaglobulinemia (XLA). Because XLA patients can live
normal and healthy lives as long as they receive immunoglobulin
replacement, BTK makes a logical target. Indeed, Ibrutinib (PCI-
32765), a BTK inhibitor, has been approved for patients with
mantle cell lymphoma and chronic lymphocytic lymphoma
(Byrd et al., 2013; Wang et al., 2013), and testing of BTK inhibi-
tors in autoimmune disorders is currently ongoing.
In addition to these immunoreceptor-activated PTKs, leuko-
cytes activate a variety of additional signaling pathways
required for function. These include phosphoinositide 3-kinase
(PI3K), protein kinase B, mammalian target of rapamycin, pro-
tein kinase C family, and mitogen-activated protein kinases
(MAPK). Many of these kinases are active areas of cancer
drug discovery. Given their broad functions, targeting this
kinase can be associated with toxicities that are tolerable for
cancer therapy but may be problematic for long-term treatment
of chronic diseases. We will limit our discussion on two targets:
PI3K-d and p38. Phosphoinositide 30 kinases (PI3K) consist of a
p85 regulatory subunit that associates with one of four—a, b, g,
or d catalytic subunits. Specifically, PI3K-d is required for B and
T cell immunity, whereas PI3K-g is critical for chemokine recep-
tor signaling in neutrophils and macrophages and for optimal
T cell responses (Rommel et al., 2007; Winkler et al., 2013).
Gain-of-function PI3KCD mutations underlie an immunologic
disorder characterized by T cell senescence and immunodefi-
ciency and may benefit from PI3K-d inhibitors (Angulo et al.,
2013). Mice deficient in PI3K-d or PI3K-g or mice treated with
selective PI3K-d and PI3K-g inhibitors are protected from devel-
opment of autoimmunity and inflammatory diseases (Banham-
Hall et al., 2012).
Idelalisib, a PI3k-d inhibitor, has demonstrated clinical efficacy
in refractory indolent non-Hodgkins lymphoma and in com-
bination with rituximab in relapsed CLL (NCT01539512 and
NCT01282424). Although acceptable for cancer patients, the
incidence of fatigue, diarrhea, fever, and rash observed in
idelalisib-treated patients is unlikely to be suitable for chronic
use in autoimmune disorders. In addition, PI3K-d has been
demonstrated to be required for Treg function and also
plays an inhibitory role in TLR signaling in macrophages
(Patton et al., 2006; Uno et al., 2010). These mechanisms
may contribute to the spontaneous colitis observed in miceCell 157, March 27, 2014 ª2014 Elsevier Inc. 237
expressing PI3K-d(D910A). Whether some of the toxicities
observed with idelalisib are on or off target will require additional
evaluation with other PI3Kd and dual PI3Kd/g inhibitors.
The MAPK family is an evolutionarily conserved pathway
comprising three tiers of sequentially activated kinases that
control broad cellular functions in response to extracellular stim-
uli. The p38 MAPK has been an area of intense focus of clinical
development for autoimmunity (Genovese, 2009). The p38
MAPKs have four isoforms: a, b, g, and d. At least seven
small-molecule inhibitors of p38 a, b, and d with different speci-
ficities have been tested in the clinic. To date, clinical efficacy
has not been observed in RA, psoriasis, or CD. Some shared
toxicities have included skin disorders, infection, liver abnormal-
ities, and gastrointestinal side effects, making these likely to be
on-target effects. A consistent finding of the various p38 inhibitor
trials is that C-reactive protein, a surrogate inflammatory marker,
decreases initially with therapy but then returns to baseline
levels, suggesting that an adaptation mechanism may occur
with p38 inhibition. Although p38 may not be a target worth
pursuing for inflammatory diseases, understanding how the
underlying mechanisms of adaptation may provide insights into
p38 biology, as well as how inflammatory diseases circumvent
therapy.
Targeting the Epigenome
Various components of immune cell signaling are individually
targeted by drugs in hope of rectifying aberrant immune
response, and those strategies have favored molecules that
are proximal to cell surface: receptors, receptor-associated ki-
nases, or extracellular cytokines. Broader approaches to expand
candidate drug targets now includemolecules whose action is in
the nucleus and on chromatin. The idea of epigenetic drugs
holds great potential because the epigenome is considered plas-
tic, responsive to perturbation, and contributes to the pathogen-
esis of many inflammatory diseases. Recent advances in next-
generation sequencing technologies have also helped to obtain
a multitude of epigenomic information as possible new bio-
markers. The current spectrum of mechanism-based epigenetic
drugs includes DNA methylation inhibitors, histone deacetylase
inhibitors (HDACi), histone methyltransferase inhibitors, and
BET protein inhibitors (BETi) (Table 1).
Acetylation of histone is one of the best-characterized read-
outs of epigenetic information that promotes relaxed chromatin
structure and active gene transcription. The organization of
enzymes that constitutes ‘‘acetylome’’ is rather tight and
includes only 18 acetyltransferases (HAT) and 18 deacetylases
(HDAC). HDAC inhibitors are widely tested as cancer therapeu-
tics and are proven to be effective in slowing cell proliferation
and inducing apoptosis in experimental settings. Although
predicting the spectrum of HDACi effect in vivo and finding
appropriate regimens for clinical benefit is challenging, an oral
HDACi (givinostat) has been demonstrated to provide some
clinical benefit in patients with systemic JIA with only mild
reversible adverse events (Vojinovic and Damjanov, 2011). Addi-
tional placebo-controlled studies will be required to assess the
effectiveness of HDACi in autoimmunity.
BET proteins (Brd2, 3, and 4) have been implicated in tran-
scriptional control of multiple inflammatory genes. JQ1 is a238 Cell 157, March 27, 2014 ª2014 Elsevier Inc.small-molecule inhibitor that binds the BET bromodomain and
blocks interactions between Brd2-4 and acetylated histones.
Treatment of macrophages with a BET inhibitor (I-BET or JQ1)
or knockdown of Brd2, 3, or 4 resulted in decreased LPS-
induced proinflammatory cytokine production (TNFa, IL-6, and
MCP) (Belkina et al., 2013; Nicodeme et al., 2010). In addition,
BET bromodomain inhibition with JQ1 blocks human Th17 differ-
entiation and function (Mele et al., 2013). As many BET small-
molecule inhibitors are being developed, the opportunity to
assess efficacy and potential toxicities of BET inhibition will be
addressed in the near future.
Conclusions and Speculation
The black box of immunology has given way to the discovery of
numerous molecules, diverse cell populations, and the identifi-
cation of signaling pathways and cell biology insights. Over the
past 40 years, this had led to numerous advances in dissecting
molecular mechanisms underlying immune and inflammatory
disease and many new therapies. ‘‘Immunology’’ has evolved
to become ‘‘molecular immunology,’’ hardly a soft science by
any measure. This has equipped us with the ability to identify
target molecules for drug design (Figures 2 and 3). In addition
to time-tested reliable compounds derived from natural sources,
we have invented and compiled a wide collection of mechanism-
based designer biologics, as well as chemically synthesized
small molecules as therapeutic options. Also, our knowledge of
biomarkers to predict and evaluate efficacy has expanded.
Nevertheless, we should not fool ourselves to believe that our
knowledge on the collection of drugs and biomarkers is sufficient
to execute precision medicine in the 21st century. There will
always be the ‘‘unknown unknowns.’’ As one example out of
many, when IL-2 was approved, we did not know about Tregs,
Th17s, and Tfh cells, as well as an essential role of IL-2 in periph-
eral tolerance. This will always be the case in science, medicine,
and drug discovery. The existence of the unknown unknowns
always needs to be borne in mind as frontiers are approached.
There will always be lessons—good (efficacy), bad (lack of
efficacy), and ugly (worsening of disease)—learned from the
bedside. Ultimately, we need to decipher the rules to choose
the right combination of drugs for the right person at the
right time.
What might the next 40 years hold? As we further advance and
refine the complexities of immunology and better understand the
heterogeneity of human diseases, what might we reflect on in
2054? Where might pluripotent cells and tissue regeneration fit
in our therapeutic armamentarium? Will we utilize induction
and remission protocols for autoimmunity to re-establish toler-
ance and immune homeostasis? Can we reverse the epigenetic
changes that occur in disease? How dowe cure these diseases?
Might we develop genetic and biomarker profiles that not only
identify disease risk but also predict when clinical disease will
strike to permit treatment before end-organ damage? Might
we be able to alter one’s microbiome or use vaccinations to alter
immunity or delete autoreactivity for those at risk? Might 2054
reflect on the ‘‘cellulardrek’’ of early 21st century? All said, it
will undoubtedly be another breathtaking 40 years built on the
integration of basic discoveries, translational insights, and
thoughtful, rigorous clinical studies.
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